Compare SCSC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | MNKD |
|---|---|---|
| Founded | 1992 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1997 | 2004 |
| Metric | SCSC | MNKD |
|---|---|---|
| Price | $53.09 | $4.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $43.00 | $8.69 |
| AVG Volume (30 Days) | 203.8K | ★ 5.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $3,846,260,000.00 | $348,966,000.00 |
| Revenue This Year | $2.60 | $35.81 |
| Revenue Next Year | $4.01 | $11.89 |
| P/E Ratio | $22.09 | ★ N/A |
| Revenue Growth | 7.79 | ★ 22.23 |
| 52 Week Low | $33.76 | $2.23 |
| 52 Week High | $53.46 | $6.51 |
| Indicator | SCSC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 70.03 | 56.60 |
| Support Level | $38.55 | $3.77 |
| Resistance Level | N/A | $4.29 |
| Average True Range (ATR) | 1.33 | 0.23 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 87.71 | 47.44 |
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.